Please use this identifier to cite or link to this item:
Title: The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
Authors: Risbridger, Gail P.
Clark, Ashlee K.
Porter, Laura H.
Toivanen, Roxanne
Bakshi, Andrew
Lister, Natalie L.
Pook, David
Pezaro, Carmel J.
Sandhu, Shahneen
Keerthikumar, Shivakumar
Quezada Urban, Rosalia
Papargiris, Melissa
Kraska, Jenna
Madsen, Heather B.
Wang, Hong
Richards, Michelle G.
Niranjan, Birunthi
O’Dea, Samantha
Teng, Linda
Wheelahan, William
Li, Zhuoer
Choo, Nicholas
Ouyang, John F. 
Thorne, Heather
Devereux, Lisa
Hicks, Rodney J.
Sengupta, Shomik
Harewood, Laurence
Iddawala, Mahesh
Azad, Arun A.
Goad, Jeremy
Grummet, Jeremy
Kourambas, John
Kwan, Edmond M.
Moon, Daniel
Murphy, Declan G.
Pedersen, John
Clouston, David
Norden, Sam
Ryan, Andrew
Furic, Luc
Goode, David L.
Frydenberg, Mark
Lawrence, Mitchell G.
Taylor, Renea A.
Issue Date: 19-Aug-2021
Publisher: Nature Research
Citation: Risbridger, Gail P., Clark, Ashlee K., Porter, Laura H., Toivanen, Roxanne, Bakshi, Andrew, Lister, Natalie L., Pook, David, Pezaro, Carmel J., Sandhu, Shahneen, Keerthikumar, Shivakumar, Quezada Urban, Rosalia, Papargiris, Melissa, Kraska, Jenna, Madsen, Heather B., Wang, Hong, Richards, Michelle G., Niranjan, Birunthi, O’Dea, Samantha, Teng, Linda, Wheelahan, William, Li, Zhuoer, Choo, Nicholas, Ouyang, John F., Thorne, Heather, Devereux, Lisa, Hicks, Rodney J., Sengupta, Shomik, Harewood, Laurence, Iddawala, Mahesh, Azad, Arun A., Goad, Jeremy, Grummet, Jeremy, Kourambas, John, Kwan, Edmond M., Moon, Daniel, Murphy, Declan G., Pedersen, John, Clouston, David, Norden, Sam, Ryan, Andrew, Furic, Luc, Goode, David L., Frydenberg, Mark, Lawrence, Mitchell G., Taylor, Renea A. (2021-08-19). The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications 12 (1) : 5049. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012–2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer. © 2021, The Author(s).
Source Title: Nature Communications
ISSN: 2041-1723
DOI: 10.1038/s41467-021-25175-5
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41467-021-25175-5.pdf4.68 MBAdobe PDF




checked on Nov 21, 2022

Page view(s)

checked on Nov 17, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons